Matches in SemOpenAlex for { <https://semopenalex.org/work/W2738202107> ?p ?o ?g. }
- W2738202107 endingPage "380" @default.
- W2738202107 startingPage "372" @default.
- W2738202107 abstract "Background. The development of radical therapy for multiple myeloma (MM) is still a pressing problem. This progressive disease requires repeated courses of therapy using drugs without cross-resistance. The prognosis of “double refractory” MM which is resistant to key antitumor drugs, first generation protease inhibitors and immunomodulating agents, remains poor. The median progression-free survival (PFS) and overall survival (OS) in this cohort of patients are 5 and 9 months, respectively. Aim. The aim was to assess the effectiveness and tolerability of pomalidomide in combination with low-dose of dexamethasone in “double refractory” relapsed/refractory multiple myeloma (RRMM). Materials & Methods. According to study protocol, 10 patients from Hematology Research Center and Federal Almazov North-West Medical Research Centre with RRMM were included in the period from September 2015 to July 2016. The median age was 62.5 years (range 48-76 years), and the median number of therapy lines was 4 (range 3-5). All patients had a disease progression after the administration of bortezomib, lenalidomide, and alkylating agents. In addition, 6 (60 %) of 10 patients received high-dose melphalan chemotherapy followed by auto-HSCT. The median number of therapy lines was 6 (range 4-15). Results. The overall response rate was 60 % and the minimum response (stabilization of the disease) was observed in 40 % of patients (IMWG criteria). The median PFS was 7.8 months; OS in 18 months was observed in 70 % of cases (the median not achieved). Treatment-associated grade III-IV hematologic toxicity was observed in 2 patients (5 episodes). Non-hematological adverse events of grade III-IV included acute coronary syndrome, deep vein thrombosis, neuropathic pain, and in 1 case acute delusional disorder, which required discontinuation of the therapy. The presence of initial cytopenia and renal failure before therapy with pomalidomide did not require the dosage reduction or discontinuation of treatment. Conclusion. Pomalidomide with low-dose dexamethasone demonstrated a high overall response rate an acceptable toxicity profile in patients with RRMM." @default.
- W2738202107 created "2017-07-31" @default.
- W2738202107 creator A5008454939 @default.
- W2738202107 creator A5013179047 @default.
- W2738202107 creator A5014860024 @default.
- W2738202107 creator A5019690250 @default.
- W2738202107 creator A5028353985 @default.
- W2738202107 creator A5028752583 @default.
- W2738202107 creator A5028920565 @default.
- W2738202107 creator A5061468914 @default.
- W2738202107 creator A5074509796 @default.
- W2738202107 creator A5088688012 @default.
- W2738202107 date "2017-01-01" @default.
- W2738202107 modified "2023-09-26" @default.
- W2738202107 title "Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of Double Refractory" @default.
- W2738202107 cites W1968439357 @default.
- W2738202107 cites W1971305591 @default.
- W2738202107 cites W1973888964 @default.
- W2738202107 cites W1975916512 @default.
- W2738202107 cites W1988265934 @default.
- W2738202107 cites W1989366736 @default.
- W2738202107 cites W1991870256 @default.
- W2738202107 cites W1997952190 @default.
- W2738202107 cites W2011871138 @default.
- W2738202107 cites W2048056023 @default.
- W2738202107 cites W2048483323 @default.
- W2738202107 cites W2055338149 @default.
- W2738202107 cites W2065718044 @default.
- W2738202107 cites W2066713758 @default.
- W2738202107 cites W2066800926 @default.
- W2738202107 cites W2091773528 @default.
- W2738202107 cites W2095109341 @default.
- W2738202107 cites W2119810076 @default.
- W2738202107 cites W2123159083 @default.
- W2738202107 cites W2125477622 @default.
- W2738202107 cites W2128903704 @default.
- W2738202107 cites W2133739087 @default.
- W2738202107 cites W2136541422 @default.
- W2738202107 cites W2140579395 @default.
- W2738202107 cites W2151595053 @default.
- W2738202107 cites W2171194005 @default.
- W2738202107 cites W2287899290 @default.
- W2738202107 cites W2326706351 @default.
- W2738202107 cites W2342194574 @default.
- W2738202107 cites W2479071444 @default.
- W2738202107 cites W2486629951 @default.
- W2738202107 cites W2525918201 @default.
- W2738202107 cites W2550270744 @default.
- W2738202107 cites W2554414226 @default.
- W2738202107 cites W2556510606 @default.
- W2738202107 cites W2578005569 @default.
- W2738202107 cites W2979734599 @default.
- W2738202107 cites W4206651001 @default.
- W2738202107 cites W4302443051 @default.
- W2738202107 doi "https://doi.org/10.21320/2500-2139-2017-10-3-372-380" @default.
- W2738202107 hasPublicationYear "2017" @default.
- W2738202107 type Work @default.
- W2738202107 sameAs 2738202107 @default.
- W2738202107 citedByCount "1" @default.
- W2738202107 countsByYear W27382021072022 @default.
- W2738202107 crossrefType "journal-article" @default.
- W2738202107 hasAuthorship W2738202107A5008454939 @default.
- W2738202107 hasAuthorship W2738202107A5013179047 @default.
- W2738202107 hasAuthorship W2738202107A5014860024 @default.
- W2738202107 hasAuthorship W2738202107A5019690250 @default.
- W2738202107 hasAuthorship W2738202107A5028353985 @default.
- W2738202107 hasAuthorship W2738202107A5028752583 @default.
- W2738202107 hasAuthorship W2738202107A5028920565 @default.
- W2738202107 hasAuthorship W2738202107A5061468914 @default.
- W2738202107 hasAuthorship W2738202107A5074509796 @default.
- W2738202107 hasAuthorship W2738202107A5088688012 @default.
- W2738202107 hasBestOaLocation W27382021071 @default.
- W2738202107 hasConcept C121332964 @default.
- W2738202107 hasConcept C126322002 @default.
- W2738202107 hasConcept C141071460 @default.
- W2738202107 hasConcept C142424586 @default.
- W2738202107 hasConcept C143998085 @default.
- W2738202107 hasConcept C197934379 @default.
- W2738202107 hasConcept C2776063141 @default.
- W2738202107 hasConcept C2776364478 @default.
- W2738202107 hasConcept C2776694085 @default.
- W2738202107 hasConcept C2777063308 @default.
- W2738202107 hasConcept C2777478702 @default.
- W2738202107 hasConcept C2778375690 @default.
- W2738202107 hasConcept C2778524551 @default.
- W2738202107 hasConcept C2778684742 @default.
- W2738202107 hasConcept C2778822529 @default.
- W2738202107 hasConcept C2780401358 @default.
- W2738202107 hasConcept C2780739268 @default.
- W2738202107 hasConcept C2780775027 @default.
- W2738202107 hasConcept C71924100 @default.
- W2738202107 hasConcept C87355193 @default.
- W2738202107 hasConcept C90924648 @default.
- W2738202107 hasConceptScore W2738202107C121332964 @default.
- W2738202107 hasConceptScore W2738202107C126322002 @default.
- W2738202107 hasConceptScore W2738202107C141071460 @default.
- W2738202107 hasConceptScore W2738202107C142424586 @default.
- W2738202107 hasConceptScore W2738202107C143998085 @default.